Point-counterpoint: Soy intake for breast cancer patients

Integrative Cancer Therapies

Volumn 1, Issue 1, 2002, Pages 90-100

  Block, Keith I ^a,b   Constantinou, Andreas ^b   Hilakivi Clarke, Leena ^c   Hughes, Claude ^d   Tripathy, Debu ^e   Tice, Jeffrey A ^e  

^a Block Center Integrative Cancer Care   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZEIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; ISOFLAVONE; PHENOL DERIVATIVE; TAMOXIFEN;

BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; DIET THERAPY; DIETARY INTAKE; ESTROGEN ACTIVITY; FEMALE; FOOD SAFETY; HORMONE SUBSTITUTION; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; PATIENT COUNSELING; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SOYBEAN;

BREAST NEOPLASMS; FEMALE; HUMANS; SOY FOODS;

EID: 0041322860     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735402001001008     Document Type: Review

References (47)

1. Kurzer MS. Soy intake and risk of breast cancer. Paper presented at: Comprehensive Cancer Care; October 19-21, 2001; Arlington, VA.
2. Trock B, Butler LW, Clarke R, Hilakivi-Clarke L. Meta-analysis of soy intake and breast cancer risk. J Nutr. 2000;130:S690-S691.
3. Lamartiniere CA, Moore J, Holland M, Barnes S. Neonatal genistein chemoprevents mammary, cancer. Exp Biol Med. 1995;208:120-123.
4. Fritz WA, Coward L, Want J, Lamartiniere CA. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis 1998;19:2151-2158.
5. Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr. 2000;71(suppl 6):S1705-S1707.
6. Hilakivi-Clarke L, Clarke R, Lippman ME. Perinatal factors increase breast cancer risk. Breast Cancer Res Treatment. 1994;31(2-3):273-284.
7. Constantinou AI, Mehta RG, Vaughan A. Inhibition of N-methyl-N-nitrosourea-induced mammary tumors in rats by the soybean isoflavones. Anticancer Res. 1996;16:3293-3298.
8. Gotoh T, Yamada K, Ito A, Yin H, Kataoka T, Kohi K. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination. Jpn J Cancer Res. 1998;89:487-495.
9. Constantinou A, Lantvit D, Lim E, Xu H, Pezzuto JM. Consumption of soy products may enhance tamoxifen's breast cancer preventive effects. Proc Am Assoc Cancer Res. 2001;42:826.
10. Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer. 1997;27:31-40.
11. Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma mda-mb-435 cells. Anticancer Res. 1999;19:1657-1662.
12. Schwartz JA, Liu G, Brooks SC. Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-reg-ulated genes. Biochem Biophys Res Comm. 1998;253:38-43.
13. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 1994;21:113-131.
14. Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res. 1998;58:4851-4857.
15. This P, De la Rochfordiere A, Clough K, Fourquet A, Magdelenat H. Phytoestrogens after breast cancer. Endocr Related Cancer. 2001;8:129-134.
16. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863-870.
17. Wilcox G, Wahlqvist ML, Burger HG, Medley G. Oestrogenic effects of plant foods in postmenopausal women. Br Med J. 1990;301:905-906.
18. Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab. 1995;80:1685-1690.
19. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab. 1999;84:3479-3484.
20. Knight DC, Howes JB, Eden JA, Howes LG. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation. Climactric. 2001;4(1):13-18.
21. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause. 2000;7:105-111.
22. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause. 2000;7:236-242.
23. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol. 1997;146:294-306.
24. Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev. 1996;5(1):63-70.
25. Xu X, Duncan AM, Merz BE, Kurzer MS. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev. 1998;7:1101-1108.
26. Duncan AM, Merz BE, Xu X, Nagel TC, Phipps WR, Kurzer MS. Soy isoflavones exert modest hormonal effects in premenopausal women. J Clin Endocrinol Metab. 1999;84:192-197.
27. Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 1996;5:785-794.
28. McMichael-Phillips DF, Harding C, Morton M, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr. 1998; 68(suppl 6):S1431-S1435.
29. Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab. 1999;84:4017-4024.
30. Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases postmenopausal hot flushes: effect of soy and wheat. Maturitas. 1995;21:189-195.
31. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol. 1998;91(1):6-11.
32. Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause. 1999;6(1):7-13.
33. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol. 2000;18:1068-1074.
34. Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet. 1997;350:990-994.
35. Zheng W, Dai Q, Custer LJ, et al. Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(1):35-40.
36. Wu AH, Ziegler RG, Nomura AM, et al. Soy intake and risk of breast cancer in Asians and Asian Americans. Am J Clin Nutr. 1998;68(suppl 6):S1437-S1443.
37. Hilakivi-Clarke L, Onojafe I, Raygada M, et al. Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer. 1999;80:1682-1688.
38. Lamartiniere CA, Zhang JX, Cotroneo MS. Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr. 1998;68(suppl 6): S1400-S1405.
39. Murrill WB, Brown NM, Zhang JX, Manzolillo PA, Barnes S, Lamartiniere CA. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis. 1996;17:1451-1457.
40. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998;58:3833-3838.
41. Santell RC, Kieu N, Helferich WG. Genistein inhibits growth of estrogen-independent human breast cancer cells in culture but not in athymic mice. J Nutr. 2000;130:1665-1669.
42. Stoll BA, Parbhoo S. Treatment of menopausal symptoms in breast cancer patients. Lancet. 1988;1:1278-1279.
43. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg. 1993;165:372-375.
44. DiSaia PJ, Odicino F, Grosen EA, Cowan B, Pecorelli S, Wile AG. Hormone replacement therapy in breast cancer. Lancet. 1993;342:1932.
45. Eden J. Should women who have had breast cancer take hormone replacement therapy? Maturitas. 1995;22(2):69-70.
46. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol. 1997;65(1):89-93.
47. Peterson G, Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 1996;7:1345-1351.